Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-020045
Filing Date
2025-02-13
Accepted
2025-02-13 17:23:48
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 6484
  Complete submission text file 0000950170-25-020045.txt   8072
Mailing Address C/O BRIDGEBIO PHARMA, INC. 3160 PORTER DR, STE 250 PALO ALTO CA 94304
Business Address
Kumar Neil (Filed by) CIK: 0001742485 (see all company filings)

Type: SCHEDULE 13G/A

Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Subject) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91059 | Film No.: 25621740
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)